Balance Sheet
Cash Flow Statement
AmortizationAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Depreciation & Amortization (CF) (2017 - 2025)

Historic Depreciation & Amortization (CF) for Ascendis Pharma A (ASND) over the last 9 years, with Q4 2025 value amounting to $5.5 million.

  • Ascendis Pharma A's Depreciation & Amortization (CF) rose 1742.03% to $5.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $19.4 million, marking a year-over-year increase of 401.0%. This contributed to the annual value of $19.4 million for FY2025, which is 550.45% up from last year.
  • As of Q4 2025, Ascendis Pharma A's Depreciation & Amortization (CF) stood at $5.5 million, which was up 1742.03% from $4.6 million recorded in Q3 2025.
  • Over the past 5 years, Ascendis Pharma A's Depreciation & Amortization (CF) peaked at $5.5 million during Q4 2025, and registered a low of $4.2 million during Q2 2021.
  • Over the past 5 years, Ascendis Pharma A's median Depreciation & Amortization (CF) value was $4.7 million (recorded in 2024), while the average stood at $4.7 million.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first skyrocketed by 9753.5% in 2021, then crashed by 1037.36% in 2024.
  • Over the past 5 years, Ascendis Pharma A's Depreciation & Amortization (CF) (Quarter) stood at $4.8 million in 2021, then decreased by 3.02% to $4.6 million in 2022, then increased by 12.47% to $5.2 million in 2023, then dropped by 10.37% to $4.7 million in 2024, then rose by 17.42% to $5.5 million in 2025.
  • Its Depreciation & Amortization (CF) was $5.5 million in Q4 2025, compared to $4.6 million in Q3 2025 and $4.7 million in Q2 2025.